Current pharmacologic management in selected neuromuscular diseases

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Historically, neuromuscular disorder care centered on diagnosis and supportive measures.
• Advancements in understanding pathophysiology and genetics have enabled targeted, disease-modifying treatments.
• This shift has improved outcomes for several neuromuscular conditions.

Purpose of the Study:

• To review current therapeutic strategies for prevalent neuromuscular disorders.
• To discuss emerging and investigational treatments for debilitating neuromuscular conditions.
• To provide an overview of treatment advancements in neurology.

Main Methods:

• Literature review of current and investigational treatments.
• Focus on amyotrophic lateral sclerosis (ALS), neuromuscular junction disorders, inflammatory myopathies, and myotonia.
• Inclusion of Duchenne muscular dystrophy and spinal muscular atrophy research.

Main Results:

• Significant disease-modifying and supportive treatments are now available for various neuromuscular disorders.
• Current treatments for ALS, neuromuscular junction disorders, inflammatory myopathies, and myotonia are detailed.
• Investigational therapies for ALS, Duchenne muscular dystrophy, and spinal muscular atrophy show promise.

Conclusions:

• Understanding disease mechanisms has revolutionized neuromuscular disorder treatment.
• A combination of current and novel therapies offers improved management for patients.
• Ongoing research continues to expand therapeutic options for neuromuscular conditions.